

PATENT
54113.8004.US01In the claims:

1-25. (Cancelled)

26. (Previously Amended) A method for improving the efficiency of *in vivo* liver cell retroviral transduction, the method comprising, inducing a semi-synchronous wave of *in vivo* liver cell proliferation by concurrently administering tri-iodothyronine (T3) and keratinocyte growth factor (KGF), and further comprising administering to the liver a retroviral vector complexed with cationic liposomes subsequent to the induction of liver cell proliferation, thereby increasing transduction efficiency.

27. (Previously Added) The method of claim 26, the cationic liposome comprising DiOctadecylamidoGlycylSpermine (DOGS).

28-50. (Cancelled)

51. (Previously Amended) A method for treating cirrhosis of the liver comprising concurrently administering to a subject an effective amount of T3 and an effective amount of KGF, thereby inducing a semi-synchronous wave of liver cell proliferation *in vivo*, and further comprising administering to a liver cell a retroviral vector complexed with cationic liposomes wherein the retroviral vector encodes hepatocyte growth factor (HGF), which treats cirrhosis of the liver.

52. (Previously Amended) The method of claim 51, wherein the effective amount of T3 ranges from about 400 µg per kg of body weight of the subject to about 40 mg per kg of body weight of the subject.

PATENT
54113.8004.US01

53. (Previously Added) The method of claim 52, wherein the effective amount of T3 is about 4 mg per kg of body weight of the subject.

54. (Previously Amended) The method of claim 51, wherein the effective amount of KGF ranges from about 100 µg per kg of body weight of the subject to about 10 mg per kg of body weight of the subject.

55. (Previously Added) The method of claim 54, wherein the effective amount of KGF is about 1 mg per kg of body weight of the subject.

56. (Previously Amended) The method of claim 51, wherein the effective amount of T3 and the effective amount of KGF is in a weight ratio of about 4:1.

57. (Previously Added) The method of claim 56, wherein the effective amount of T3 is in a dose of about 4 mg per kg of body weight of the subject and the effective amount of KGF is in a dose of about 1 mg per kg of body weight of the subject.

58. (Currently Amended) The method of claim 57, wherein the T3 and KGF is are administered subcutaneously.

59. (Currently Amended) The method of claim 57, wherein the T3 and KGF is are administered intravenously.

60. (Currently Amended) The method of claim 57, wherein the T3 and KGF is are administered intramuscularly.

61. (Currently Amended) The method of claim 57, wherein the T3 and KGF is are administered intraperitoneally.

PATENT
54113.8004.US01

62. (Currently Amended) The method of claim 57, wherein the T3 and KGF is
are administered directly into the liver.

63. (Previously Added) The method of claim 51, the cationic liposome
comprising DiOctadecylamidoGlycylSpermine (DOGS).

64. (Currently Amended) The method of claim 51, wherein the retroviral vector is
administered between about 6 hours and 14 days after administration of the T3 and KGF.

65. (Currently Amended) The method of claim 51, wherein the retroviral vector is
administered between about 24 hours and 8 days after administration of the T3 and KGF.

66-68. (Cancelled)